Inflammatory Response in Islet Transplantation

Table 1

Anti-inflammatory agents in clinical allogeneic islet cell transplantation.

Publication year	Pt number	Anti-inflammatory agents	Dose of anti-inflammatory agents	Induction therapy	Maintenance therapy	Major outcomes	References
2005	8	Etanercept	50 mg i.v. pretransplant and 25 mg s.c. on days 3, 7, and 10	rATG; Daclizumab	Sirolimus; Tacrolimus; MMF	100% II after single infusion	[130]
2005	8	Infliximab	5 mg/kg i.v. pretransplant	Daclizumab	Sirolimus; Tacrolimus	7/8 recipients achieved II	[131]
2008	7	Infliximab or Etanercept	5 mg/kg i.v. pretransplant or 50 mg i.v. pretransplant and 25 mg s.c. twice weekly for 2 weeks	Daclizumab	Sirolimus; Tacrolimus; (Low-dose steroids for 3 pts)	6/7 recipients achieved II	[146]
2008	3	Etanercept	50 mg i.v. pretransplant and 25 mg s.c. twice weekly for 2 weeks	Alemtuzumab	Sirolimus; Tacrolimus; MMF	2/3 recipients achieved II	[147]
2008	6	Etanercept	50 mg i.v. pretransplant and 24 mg s.c. on days 3, 7, and 10	rATG (for first transplant); Daclizumab (for 2nd transplant)	Cyclosporine; Everolimus	5/6 recipients achieved II	[148]
2008	6	Etanercept	50 mg i.v. pretransplant and 24 mg s.c. on days 3, 7 and 10	Daclizumab	Sirolimus; Tacrolimus	6/6 recipients achieved II	[149]
2011	3	Etanercept and anakinra	50 mg i.v. pretransplant and 25 mg s.c. on days 3, 6, and 10 and 100 mg i.v. pretransplant and 100 mg s.c. for 7 days after transplant	rATG	Tacrolimus; MMF	3/3 recipients achieved II	[135]
2012*	22	Anti-TNF-α	NA	T-cell depletion protocol	NA	50% of recipients kept II for 5 years	[132]

i.v. indicates intravenous injection; s.c., subcutaneous injection; rATG, rabbit antithymocyte globulin; MMF, mycophenolate mofetil; II, insulin independence; TNF, tumor necrosis factor.
*Based on collaborative islet transplant registry, collecting data from multiple centers.